Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Radiation Oncology
•
Gastrointestinal Cancers
•
Medical Oncology
How would you treat a patient with a synchronous T1N2 non-small cell lung cancer and a T3N1 mid-rectal adenocarcinoma (MMR intact)?
What would be an optimal sequence of therapies, and what chemotherapy regimen may be best?
Related Questions
What treatment sequence do you follow for patients with rectal cancer who are candidates for both PROSPECT and TNT/Watch and wait?
In an N+ rectal adenocarcinoma treated via PROSPECT with neoadjuvant FOLFOX with omission of CRT and no treatment response in the primary on pathology (ypN+), would you offer adjuvant chemotherapy or chemo-radiation?
Would you consider proton therapy as part of TNT for rectal cancer?
Would you consider delaying tarlatamab initiation in a patient with ES SCLC who recently completed RT for CNS disease, given the concern for immune effector cell-associated neurotoxicity syndrome (ICANS)?
Are you incorporating TTFields into treatment protocols for locally advanced pancreatic cancer based on the PANOVA-3 study?
How was treatment response assessed on the PROSPECT trial?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
Which patients, if any, treated according to PROSPECT for an early stage rectal cancer, would you offer surveillance if they achieved cCR after neoadjuvant chemotherapy?
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
Would you change treatment approach for rectal cancer with an associated intussusception?